TABLE 1.
Susceptiblities of PCV-selected HSV-1 in MRC-5 cells
| SC16 isolateb | IC50 (μg/ml)a
|
|||||
|---|---|---|---|---|---|---|
| ACV (0.2) | PCV (0.3) | BVDU (<0.01) | FOS (29.1) | Ara-A (1.5) | CDV (0.3) | |
| 1P1 | >100 | >100 | 12.6 | 31.8 | 8.3 | 0.6 |
| 1P2 | >100 | >100 | >50.0 | 20.7 | 8.1 | 0.7 |
| 1P3-A | 62.1 | 55.4 | >10.0 | 45.0 | 1.6 | 0.4 |
| 1P3-B | 48.4 | 54.4 | >50.0 | 81.3 | 1.9 | 0.1 |
| 1P4 | >100 | 39.2 | 10.9 | 70.0 | 3.3 | 0.1 |
| 1P5 | 20.0 | >100 | 8.4 | 10.0 | 0.5 | 0.1 |
| 1P6 | >100 | >100 | 16.7 | 8.3 | 4.3 | 0.4 |
| 1P7 | >100 | >100 | 33.2 | 11.6 | 4.6 | 0.5 |
| 1P8 | >100 | 62.1 | 27.5 | 84.0 | 2.1 | 0.5 |
| 1P9 | 88.4 | 58.8 | 23.0 | 43.1 | 1.6 | 0.7 |
| 1P10 | >100 | >100 | 25.5 | 52.1 | 1.9 | 0.4 |
| 1P11 | 0.11 | 0.4 | <0.01 | 38.8 | 1.2 | 0.4 |
| 1P12 | >100 | >100 | 28.0 | 25.2 | 4.6 | 0.5 |
a
Susceptibility data for wild-type HSV-1 SC16 are from the initial virus preparation used for these studies and are listed in parentheses.
b
Each plaque isolate was purified from a unique starting well, except 1P3-A and 1P3-B, which are separate plaque isolates purified from the same well.